DJ Hardman & Co Research on International Biotechnology Trust (IBT): Low FDA activity may drive further M&A
Hardman & Co Research Hardman & Co Research on International Biotechnology Trust (IBT): Low FDA activity may drive further M&A 08-Dec-2022 / 07:47 GMT/BST
-----------------------------------------------------------------------------------------------------------------------
Hardman & Co Research on International Biotechnology Trust (IBT):
Low FDA activity may drive further M&A
IBT was established in 1994 to provide institutional and retail investors with the opportunity to participate in global biotechnology and life science companies, from venture-stage early drug discovery via venture capital funds (SV Health Investors) through to global, multinational biotechnology companies. The trust's main aim is to generate capital growth, while minimising risk, through a diversified portfolio and an experienced investment team. Over the last five years, IBT's NAV per share has increased 25%, while the share price has increased 32% over the same period - the superior returns generally reflected by a reduction in the share price discount.
Please click on the link below for the full report:
https://hardmanandco.com/research/corporate-research/low-fda-activity-may-drive-further-ma/
If you are interested in meeting the company, you can register your interest by clicking on the above link
To contact us:
Hardman & Co Contact:
1 Frederick's Place
Martin Hall
London mh@hardmanandco.com
EC2R 8AE
+44(0)203 693 7075
www.hardmanandco.com
Follow us on Twitter @HardmanandCo
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.
-----------------------------------------------------------------------------------------------------------------------
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
End of Announcement - EQS News Service
1507847 08-Dec-2022
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1507847&application_name=news
(END) Dow Jones Newswires
December 08, 2022 02:47 ET (07:47 GMT)